Multiple lines of evidence indicate that immunotherapies, including checkpoint inhibitors such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), are efficient strategies to shoot tumor cells (1). The gene discussed is CTLA4; the disease is neoplasm.